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Atrazine, a triazine herbicide used primarily in
corn production (Frank and Sirons 1979), is
the most common pesticide contaminant of
groundwater and surface water (Fenelon and
Moore 1998; Hennion M, Pichon V, Legeay P,
Cohen M, unpublished data; Kolpin et al.
1998; Lode et al. 1995; Miller et al. 2000;
Müller et al. 1997; Solomon et al. 1996;
Thurman and Cromwell 2000). In addition
to its high use, ubiquitous contamination of
aquatic environments, persistence, and mobil-
ity, atrazine is a concern because it is a potent
endocrine disruptor in wildlife and laboratory
rodents. 
A U.S. Environmental Protection Agency
(EPA) laboratory ﬁrst concluded that atrazine
was an endocrine disruptor in the year 2000: 
Atrazine tested positive in the pubertal male
screen that the EDSTAC [U.S. EPA Endocrine
Disruptor Screening and Testing Advisory
Committee] is considering as an optional screen
for endocrine disruptors. (Stoker et al. 1999)
Among other endocrine-disrupting effects
(Babic-Gojmerac et al. 1989; Cooper et al.
1999, 2000; Cummings et al. 2000;
Friedmann 2002; Kniewald et al. 1979, 1995;
Narotsky et al. 2001; Shafer et al. 1999; S ˇimic
et al. 1991; Stoker et al. 1999, 2000), atrazine
disrupts androgen- and estrogen-mediated
processes. Atrazine has a low affinity for
androgen and estrogen receptors (Roberge
et al. 2004; Tennant et al. 1994) and, thus, is
not a receptor agonist or antagonist. Atrazine
reduces androgen synthesis and action via sev-
eral mechanisms (Babic-Gojmerac et al. 1989;
Kniewald et al. 1979, 1980, 1995; S ˇimic et al.
1991) and it increases estrogen production
(Crain et al. 1997; Heneweer et al. 2004;
Keller and McClellan-Green 2004; Sanderson
et al. 2000, 2001, 2002; Spano et al. 2004). 
Atrazine increases aromatase levels by
binding to and inhibiting phosphodiesterase
(Roberge et al. 2004; Sanderson et al. 2000,
2001), resulting in elevated cAMP in some
human cancer cell lines. Elevated cAMP
results in increased transcription of the aro-
matase gene CYP19 [cytochrome P450, family
19, subfamily A, polypeptide 1 (CYP19A1);
UniGene Hs.654384 (UniGene 2007) or
GenBank NM_000103 (GenBank 2007)],
increased aromatase activity, and, ultimately,
increased estrogen production. The molecular
mechanism is not completely understood,
however, and effects vary between cell types
(Morinaga et al. 2004). In this article we
address the role of the important transcription
factor, steroidogenic factor 1 (SF-1), in
atrazine-induced aromatase expression. 
Materials and Methods 
Experiments. Experiment 1: SF-1 levels in
atrazine-responsive and -nonresponsive cells.
To test the hypothesis that SF-1 is required
for atrazine-induced aromatase expression, we
examined SF-1 levels in atrazine-responsive
H295R adrenocortical carcinoma cells and
nonresponsive KGN granulosa cells. Endoge-
nous SF-1 mRNA was analyzed by real-time
polymerase chain reaction (PCR) with the
relative copies of SF-1 to β-actin in KGN
cells set to 1. The relative copies of SF-1 to
β-actin in H295R cells were calculated
accordingly. SF-1 protein levels were con-
ﬁrmed by Western blot analysis.
Experiment 2: Induction of luciferase
activity by atrazine and simazine via aro-
matase promoter II in H295R cells. We trans-
fected H295R and NIH/3T3 cells with a 4.0
kb aromatase promoter II (ArPII) luciferase
reporter (pGL3-ArPII4.0) with or without co-
transfection with human SF-1 (pcDNA3.1-
hSF-1). This experiment was designed to
determine whether SF-1 would increase the
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BACKGROUND: Atrazine is a potent endocrine disruptor that increases aromatase expression in some
human cancer cell lines. The mechanism involves the inhibition of phosphodiesterase and sub-
sequent elevation of cAMP. 
METHODS: We compared steroidogenic factor 1 (SF-1) expression in atrazine responsive and non-
responsive cell lines and transfected SF-1 into nonresponsive cell lines to assess SF-1’s role in
atrazine-induced aromatase. We used a luciferase reporter driven by the SF-1–dependent aromatase
promoter (ArPII) to examine activation of this promoter by atrazine and the related simazine. We
mutated the SF-1 binding site to conﬁrm the role of SF-1. We also examined effects of 55 other
chemicals. Finally, we examined the ability of atrazine and simazine to bind to SF-1 and enhance
SF-1 binding to ArPII.
RESULTS: Atrazine-responsive adrenal carcinoma cells (H295R) expressed 54 times more SF-1 than
nonresponsive ovarian granulosa KGN cells. Exogenous SF-1 conveyed atrazine-responsiveness to
otherwise nonresponsive KGN and NIH/3T3 cells. Atrazine induced binding of SF-1 to chromatin
and mutation of the SF-1 binding site in ArPII eliminated SF-1 binding and atrazine-responsive-
ness in H295R cells. Out of 55 chemicals examined, only atrazine, simazine, and benzopyrene
induced luciferase via ArPII. Atrazine bound directly to SF-1, showing that atrazine is a ligand for
this “orphan” receptor. 
CONCLUSION: The current findings are consistent with atrazine’s endocrine-disrupting effects in
fish, amphibians, and reptiles; the induction of mammary and prostate cancer in laboratory
rodents; and correlations between atrazine and similar reproductive cancers in humans. This study
highlights the importance of atrazine as a risk factor in endocrine disruption in wildlife and repro-
ductive cancers in laboratory rodents and humans. 
KEY WORDS: aromatase, atrazine, breast cancer, cAMP, CYP19, endocrine disruptor, hermaphro-
ditism, prostate cancer, SF-1. Environ Health Perspect 115:720–727 (2007). doi:10.1289/ehp.9758
available via http://dx.doi.org/ [Online 5 February 2007]ability of atrazine to induce gene expression via
ArPII using a luciferase promoter.
Experiment 3: Other environmental con-
taminants. We used a luciferase activity assay
[NIH/3T3 cells co-transfected with 4.0 kb
ArPII reporter (pGL3-ArPII4.0) and human
SF-1 (pcDNA3.1-hSF-1)] to screen 55 envi-
ronmental contaminants. Cells were exposed
to the solvent (DMSO) or 10–6 mol/L
forskolin [protein kinase A (PKA) agonist]
with or without each of 55 chemicals at
10–5 mol/L (except for 10–7 mol/L tributyltin
and 10–7 mol/L triphenyltin) for 48 hr before
the luciferase assay was performed.
Experiment 4: Atrazine induction of
aromatase expression and activity in KGN
ovarian cells. We used KGN ovarian cells to
examine aromatase expression in response to
atrazine exposure. SF-1 infection of KGN
cells was used to determine whether this tran-
scription factor was sufficient to support
atrazine-induced aromatase in this otherwise
atrazine nonresponsive cell line.
Experiment 5: Atrazine-enhanced SF-1
binding to ArPII. We conducted a chromatin-
immunoprecipitation (ChIP) assay to deter-
mine whether atrazine and simazine increased
binding of SF-1 to ArPII. 
Experiment 6: Binding of atrazine to
SF-1. We used surface plasmon resonance
(SPR) to examine the ability of atrazine to bind
directly to SF-1 as a second mechanism by
which atrazine could induce gene expression
via ArPII. We used quartz crystal balance tech-
niques to conﬁrm results of the SPR study.
Chemical standards. Chemicals standards
for testing in cell lines were obtained from
Wako Pure Chemical Co. (Osaka, Japan) and
Accu Standard, Inc. (New Haven, CT, USA).
We examined the effects of these chemicals, at
a concentration of 10–5 mol/L (except for
10–7 mol/L tributyltin and 10–7 mol/L tri-
phenyltin). The chemicals were dissolved in
ethanol (except for aldicarb, atrazine, and
simazine, which were dissolved in DMSO) at
the original concentration of 10–2 mol/L. The
adenylyl cyclase activator forskolin was pur-
chased from Sigma-Aldrich, Inc. (St. Louis,
MO, USA) and was dissolved in DMSO.
Cell lines. The human ovarian granulosa-
like tumor cell line (KGN) was established
and maintained as previously reported (Nishi
et al. 2001). H295R adrenal carcinoma cells
(ATCC CRL 2128), NIH/3T3 mouse ﬁbro-
blasts (ATCC CRL1658), and sf21 insect cells
(ATCC CRL1711) were all obtained from the
American Type Culture Collection (ATCC;
Manassas, VA, USA) and grown under culture
conditions prescribed by the ATCC. 
Plasmids and constructs. We constructed
a luciferase reporter containing 4.0 kb of the
5´-flanking sequence of ArPII as previously
described (Fan et al. 2005a). A 4-kb human
SF-1 promoter luciferase reporter was
established previously (Oba et al. 2000). We
purchased the Renilla luciferase reporter plas-
mid pRL-CMV from Promega (Madison,
WI). An adenovirus construct expressing
bovine SF-1 (adeno-SF-1) and another
expressing β-galactosidase (adeno-LacZ) were
prepared as described previously (Gondo et al.
2004). 
Quantification of mRNA. Total RNA
from cells was isolated and reverse-transcribed
to cDNA; relative aromatase mRNA copy
numbers to β-actin were then analyzed by real-
time PCR following the protocol described
previously (Fan et al. 2005b). Primers for
human aromatase were 5´-ACG CAG GAT
TTC CAC AGA AGA G-3´ (forward) and
5´-CTT CTA AGG CTT TGC GCA TGA
C-3´ (reverse). Primers for human β-actin were
5´-AAA CTA CCT TCA ACT CCA TC-3´
(forward) and 5´-ATG ATC TTG ATC TTC
ATT GT-3´ (reverse). Endogenous human SF-
1 mRNA copies in H295R and KGN cells
were also determined by the same method.
Primers for SF-1 were 5´-CAG CCT GGA
TTT GAA GTT CC-3´(forward) and 5´-TTC
GAT GAG CAG GTT GTT GC-3´ (reverse).
Western blots. Western blots were
conducted using standard techniques. The
anti-SF-1 antibody used was provided by
K. Morohashi (National Institution for Basic
Biology, Okazaki, Japan).
Relative luciferase reporter assay. For the
55 environmental chemical-screening studies,
we co-transfected each of three 10-cm2 dishes
containing 70% conﬂuent NIH-3T3 cells with
1.5 µg ArPII reporter (PGL3-ArPII4.0), 1.5 µg
pcDNA3.1-hSF-1, and 10 ng pRL-CMV by
Effectence transfection reagent (QIAGEN,
Miami, FL, USA) following the manufacturer’s
protocol. Twenty-four hours after transfection,
cells in all three dishes were trypsinized, mixed
together, and reseeded to 24-well plates
(approximately 1.0 × 105 cells/well). DMSO,
10–6 mol/L forskolin, or 10–5 mol/L test
chemicals plus forskolin was added to the cells,
and a luciferase assay was performed 48 hr
later. The basic technical details for other rela-
tive dual-luciferase assays in this study are as
follows. On the ﬁrst day, 0.75 × 105 cells/well
in 0.5 mL growth medium were seeded into
24-well plates. On the second day, 0.4 µg
PGL3-ArPII, 1.0 ng pRL-CMV, and 0.1 µg
pcDNA3.1-hSF-1, or an equal-molar amount
of empty vector pcDNA3.1, were transiently
co-transfected to each well using the
Effectence transfection reagent. On the third
day, the culture medium was replaced with
fresh medium in the presence of proper chem-
icals or its solvent DMSO. On the fifth day
(48 hr after chemical treatment), the cells were
lysed in 100 µL/well passive lysis buffer, and
the luciferase assay was performed in accor-
dance with the protocol of the Dual-Luciferase
Reporter Assay System (Promega) using a
Lumat LB 9507 luminometer (Berthold
Technologies, Bad Wildbad, Germany). The
firefly luciferase activity produced by PGL3-
ArPII in identically treated triplicate samples
was normalized for the renilla luciferase activity
produced by pRL-CMV. The data shown rep-
resent at least three independent experiments. 
Aromatase assay. We measured 3H2O
released upon conversion of [1β-3H] andro-
stenedione to estrone to measure aromatase
activity, as described previously (Mu et al.
2000). Briefly, the cells were cultured in a
24-well dish in Dulbecco’s modified Eagle’s
medium/Ham’s F-12 with 10% fetal bovine
serum in the presence of atrazine, simazine, or
DMSO and incubated for 40 hr. The cells
were then incubated with [1β-3H] androstene-
dione for an additional 6 hr. The medium was
extracted with chloroform and centrifuged.
The aqueous phase was then mixed with 5%
charcoal/0.5% dextran and incubated for
30 min. The mixture was subsequently cen-
trifuged, and the supernatant was added to
5 mL scintillation fluid and assayed for
radioactivity. The amount of radioactivity in
3H2O was standardized from the protein con-
centration determined using a protein assay kit
(Bio-Rad Laboratories, Hercules, CA, USA). 
ChIP assay. ChIP assays were performed
using the ChIP assay kit from Upstate Bio-
technology (Lake Placid, NY, USA) following
the protocol provided by the manufacturer,
with some modiﬁcations. Brieﬂy, H295R cells
were seeded in 10-cm2 dishes and treated with
10–5 mol/L atrazine, simazine, or DMSO for
48 hr. Cells were then cross-linked with 1%
formaldehyde for 60 min, washed with chilled
phosphate-buffered saline (PBS), resuspended
in 200 µL SDS lysis buffer, and sonicated six
times for10 sec each at 60% maximum setting
of the sonicator (Handy Sonic-UR-20P;
TOMY SEIKO Co., Ltd., Tokyo, Japan).
Sonicated cell supernatant was diluted 10-fold,
and 1% (20 µL) of the total diluted lysate was
used for total genomic DNA as input DNA
control. The rest (1,980 µL) was then sub-
jected to immunoclearing by 75 µL salmon
sperm DNA/protein A agarose–50% slurry for
30 min at 4°C. Immunoprecipitation was per-
formed overnight at 4°C with 3 µg anti-SF-1
antibody (courtesy of K. Morohashi, National
Institution for Basic Biology, Okazaki, Japan).
For the negative control, we used normal rab-
bit IgG (Santa Cruz Biotechnology) instead of
the antibody. Precipitates were washed sequen-
tially for 5 min each in low-salt, high-salt, and
lithium chloride immune complex wash
buffers, and finally washed twice with Tris/
EDTA buffer. Histone complexes were then
eluted from the antibody by freshly prepared
elution buffer (1% SDS, 0.1 M NaHCO3).
Histone-DNA cross-links (including the input
samples) were reversed by 5 M NaCl at 65oC
for 4 hr. DNA fragments were extracted with a
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We used 1 µL from a 30-µL DNA extraction
for PCR (28 cycles) and primed by sequences
as follows: forward, 5´-GGG AAG AAG ATT
GCC TAA AC-3´; reverse, 5´-TGT GGA
AAT CAA AGG GAC AG-3´; the PCR size
was 401 bp. Immunoprecipitated DNA sam-
ples were then set to real-time PCR analysis to
quantify the relative amount to their corre-
sponding input controls with a LightCycler
(Roche Diagnostics GmbH, Mannheim,
Germany) according to the manufacturer’s
instructions. Brieﬂy, 1 µL immunoprecipitated
DNA sample (or H2O as negative control),
was placed into a 20-µL reaction volume con-
taining 1 µL of each primer (10 µM) and 2 µL
LightCycler-FastStart DNA Master SYBR
Green I (Roche), which includes nucleotides,
Tag DNA polymerase, and buffer. Input sam-
ples were ampliﬁed simultaneouslyas the inter-
nal controls. Real-time PCR data for each
immunoprecipitated sample were calculated as
a ratio to the corresponding input sample.
Briefly, threshold values (crossing line)
obtained where ﬂuorescent intensity was in the
geometric phase, cycle number at the crossing
point of an immunoprecipitated sample (Cip),
and the corresponding input sample (Cco)
were determined via LightCycler software, ver-
sion 3.5. The relative amount of the immuno-
precipitated sample (Aip) to input sample was
calculatedby the formula Aip = 2(Cco – Cip). 
We also performed deletion–mutation
assays on the 4.0 kb ArPII to identify the
responsible site for atrazine and simazine stim-
ulation. The promoter was cut down using
restriction enzymes (SnaBI, AﬂII, or EcoRI) to
make three other ArPII reporters with lengths
of 3.1 kb, 2.0 kb, and 1.0 kb, respectively.
Responsiveness was indicated by 10–5 mol/L
atrazine-induced multiples of relative luciferase
activity (RLA) mediated by each promoter.
The 516 bp ArPII luciferase reporter (PGL3-
PII-516) and the PGL3-PII-516-SF1-M (of
which the SF-1 site was mutated from
AGGTCA to ATTTCA) were provided cour-
tesy of E.R. Simpson (Monash University,
Melbourne, Australia) (Rubin et al. 2002).
Surface plasmon resonance. We used
baculovirus to express the Flag containing
SF-1 fusion protein in insect sf21 cells. The
baculovirus mouse SF-1 expression vector was
established as described previously (Komatsu
et al. 2004). Sf21 cells were infected with bac-
ulovirus, and extracts were prepared 72 hr
postinfection. The Flag-SF-1 fusion protein
was puriﬁed by afﬁnity chromatography with
anti-Flag M2 antibody-agarose (Sigma,
St. Louis, MO, USA) and eluted with
150 µg/mL 3 × Flag peptide (Sigma). The
binding afﬁnity of atrazine to Flag-SF-1 was
measured by Surface Plasmon Resonance
(SPR) using a Biocore T100 biosensing system
(Biocore, Tokyo, Japan) following the stan-
dard manufacturer’s protocol. The Biocore
T100 can investigate interactions involving
binding partners with molecular weight as low
as 100 Da. Purified Flag-SF-1 protein
(11700–14250 resonance units) was immobi-
lized on a Series S Sensor Chip (CM5;
Biocore) by using the Amincoupling kit
(Biocore). Chemicals [atrazine as the one of
interest; 1,2-dihexadecanoyl-n-glycero-3-phos-
phocholine (16PC) as the positive control;
benzophenone and p-nitrotoluene as negative
controls) were dissolved in PBS (pH 7.4) +
5% DMSO at various concentrations. PBS +
5% DMSO was used as the mobile phase
medium (running buffer) at a flow rate of
30 µL/min at 25°C. Binding of chemicals dis-
solved in the running buffer to immobilized
Flag-SF-1 was monitored in real time by
measuring changes in resonance units. The
sensorgrams for the reference channel (non-
SF-1–bearing CM5 chip) were subtracted
simultaneously from the sensorgrams for sens-
ing channel (SF-1 bearing CM5 chip). All
data were automatically analyzed by Biocore
T100 evaluation software (version 1.00).
Quartz crystal microbalance. We exam-
ined binding of atrazine to SF-1 using a
27-MHz quartz crystal microbalance (QCM;
Initium Co., Tokyo, Japan). SF-1 was immo-
bilized onto a QCM electrode according to
the manufacturer’s protocol. The electrode
was soaked in 8 mL PBS buffer (pH 7.4) and
monitored continuously for QCM frequency
change at 25°C. After the frequency change
was stabilized, chemicals of interest were
added to the solution and we assessed the
time course of frequency change in response
to the addition of chemicals. 
Statistical analysis. All data are expressed
as the mean ± SD and were evaluated by one-
way analysis of variance (ANOVA) or two-
tailed Student’s t-test, followed by post hoc
comparisons with Fisher’s protected least-
significant-difference test. p < 0.05 was con-
sidered statistically signiﬁcant.
Fan et al.
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Figure 2. Effects of atrazine and simazine (10–5 mol/L each for A and B; as marked for C) of three cell types, measured by RLA. (A) Atrazine and simazine stimu-
lated ArPII in H295R cells without exogenous SF-1 supplementation. (B) ArPII response to atrazine and simazine in NIH-3T3 cells required coexpression of SF1.
(C) Atrazine and simazine stimulation of SF-1–mediated ArPII in SF-1–co-transfected NIH-3T3 cells was dose dependent. Both triazines were effective at concen-
trations as low as 10–7 mol/L (ANOVA, p < 0.05). Bars show mean ± SD; letters above bars indicate statistical groups (ANOVA, p < 0.05).
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Figure 1. Effects of SF-1 on induction of CYP19 by
10–5 mol/L atrazine. (A) SF-1 expression was signif-
icantly higher (54-fold; ANOVA, p < 0.05) in
atrazine-responsive H295R cells compared with
atrazine-nonresponsive KGN cells. (B) SF-1 pro-
tein levels were also higher in H295R cells as
determined by Western blot. 
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Experiment 1. Although the nonresponsive
KGN granulosa cells expressed SF-1 mRNA,
real-time PCR revealed that copy numbers of
SF-1 mRNA were 54 times lower in these
atrazine nonresponsive cells compared
with the atrazine-responsive H295R adreno-
cortical carcinoma cells (ANOVA, p < 0.05;
Figure 1A). A concomitant Western-blot
analysis revealed markedly higher SF-1 pro-
tein levels in atrazine-responsive H295R
adrenocortical carcinoma cells compared with
the nonresponsive KGN granulosa cells
(Figure 1B).
Experiment 2. Atrazine and simazine (a
similar triazine herbicide) both induced
luciferase activity in H295R adrenocortical
carcinoma cells (which express SF-1 endoge-
nously) without co-transfection of SF-1
(ANOVA, p < 0.05; Figure 2A). Neither
atrazine nor simazine affected ArPII in the
absence of SF-1 coexpression in NIH/3T3
fibroblast cells, which lack endogenous SF-1
expression (ANOVA, p > 0.05; Figure 2B).
Once SF-1 was present (pcDNA3.1-hSF-1–
co-transfected cells), however, there was a
4.2-fold elevation in basal activity and increased
responsiveness to atrazine and simazine
(ANOVA, p < 0.05; Figure 2B). Both atrazine
and simazine increased SF-1–enhanced ArPII
activity 2.25- and 2.26-fold, respectively
(ANOVA, p < 0.05; Figure 2B) in the
pcDNA3.1-hSF-1–transfected NIH/3T3 cells.
The 2.2- and 2.3-fold are similar to the chloro-
triazine-stimulation of ArPII activity in
H295R (SF-1 nontransfected). Thus, the
ArPII response to atrazine and simazine is SF-1
dependent. Furthermore, in these SF-1
coexpressing NIH/3T3 cells, the atrazine/
simazine stimulation of SF-1–mediated ArPII
was dose dependent, with both chemicals
effective at concentrations as low as 10–7 mol/L
(ANOVA, p < 0.05; Figure 2C). 
Experiment 3. We previously showed that
activation of the cAMP-PKA signal potenti-
ates SF-1 transactivation by modifying the
interactions between SF-1 and its cofactors,
and PKA-induced activation of ArPII requires
SF-1 (Fan et al. 2004). We studied whether
any other environmental contaminants
affected PKA-enhanced SF-1–mediated ArPII
expression. In a luciferase reporter system, in
which the 4.0-kb human ArPII luciferase
reporter and pcDNA3.1-hSF-1 were coex-
pressed in NIH-3T3 ﬁbroblast cells, 55 known
environmental hormone chemicals were
screened; among them, atrazine and the related
triazine, simazine, stimulated the forskolin-
enhanced SF-1–mediated ArPII expression by
a factor of two to three (ANOVA, p < 0.05;
Figure 3). As shown in Figure 2, the results
were repeated and conﬁrmed in the absence of
forskolin. A third chemical, benzopyrene, also
signiﬁcantly induced luciferase (p < 0.05) but
was less potent than the two triazines. Nonyl-
phenol, di-n-butyl phthalate (DBP), dicyclo-
hexylpthalate (DCHP), fenevalerate, and
octylphenol all decreased luciferase activity
(ANOVA, p < 0.05; Figure 3).
Experiment 4. Adeno-SF-1–infected KGN
ovarian granulosa cells had an elevated basal
level of aromatase expression (ANOVA,
p < 0.05) and showed a 3.78- and a 4.94-fold
increase in responsiveness to atrazine and
simazine, respectively (ANOVA, p < 0.05;
Figure 4A). The control (adeno-lacZ) vector
had no effect (ANOVA, p > 0.05; Figure 4A).
Thus, exogenous SF-1 conferred aromatase
responsiveness to atrazine and simazine in oth-
erwise atrazine-nonresponsive KGN granulosa
cells. Furthermore, adeno-SF-1–infected
KGN ovarian granulosa cells showed a signiﬁ-
cant increase in aromatase activity (ANOVA,
p < 0.05; Figure 4B) as determined by a tritium
release assay. Thus, in line with the results of
promoter assays shown in experiment 2, the
mRNA expression of CYP19, as well as the
Atrazine, breast cancer, and prostate cancer
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Figure 3. RLA (mean ± SD) of endocrine disruptors that affect forskolin-enhanced SF-1–mediated ArPII presented as chemicals with no effect on luciferase activ-
ity, those with signiﬁcantly induced luciferase activity, or those with signiﬁcantly inhibited luciferase activity as determined by ANOVA, followed by Fisher’s pro-
tected least-significant-difference post hoc test (p < 0.05). Abbreviations: 2,4-DCP, 2,4-dichlorophenol; 2,4-PA, 2,4-dichlorophenoxy acetic acid; BHC, benzene
hexachloride; DBCP, dibromochloropropane; DDD, 1,1-dichloro-2,2-bis(4-chlorophenyl)ethane; DDE, 1,1-dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethylene;
DDT, 1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane; DEHP, di-2-(ethyl-hexyl)-phthalate; DOA, dioctyl adipate; NAC, N-acetylcysteine; NIP, dinitrophenyl-phospho-
rothioate; TMBP, 4-(1,1,3,3- tetramethylbutyl) phenol. All chemicals were examined at ecologically relevant concentrations: 10–5 mol/L for all chemicals, except
tributyltin and triphenyltin, which were examined at 10–7 mol/L.
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Aenzymatic activities of aromatase, becomes
responsive to both atrazine and simazine when
SF-1 is exogenously expressed in KGN cells,
which are otherwise atrazine nonresponsive. 
Experiment 5. ArPII DNA sequences in
the chromatin immunoprecipitates were signif-
icantly enriched by either simazine or atrazine,
demonstrating that the triazines enhanced
binding of SF-1 to ArPII (ANOVA, p < 0.05;
Figure 5A, B). The responsiveness to atrazine
and simazine was well-preserved when ArPII
was reduced to 516 bp; however, when the
SF-1 binding site (AGGTCA) was mutated to
ATTTCA (a treatment that impairs SF-1 bind-
ing to ArPII), the responsiveness to atrazine and
simazine was eliminated (ANOVA, p < 0.05;
Figure 5C). 
Experiment 6. The known SF-1 ligand
16PC was examined as a positive control for
comparison with atrazine and two negative
controls (p-nitrotoluene and benzophenone).
A dose-dependent interaction between the
control ligand (16PC) and immobilized SF-1
was observed by SPR (Figure 6A). Of the test
ligands, only atrazine caused a significant
(Figure 6B) and dose-dependent SPR response
(Figure 6C). A quartz-crystal microbalance
study conﬁrmed that both 16PC and atrazine
bound SF-1, whereas the solvent and negative
control p-nitrotoluene did not (Figure 6D).
The atrazine response was signiﬁcantly lower
than the positive control (16PC), but experi-
ments such as scintillation proximity assays
using radioactively labeled atrazine are required
to determine the precise dissociation constant. 
Discussion
Atrazine increases aromatase by binding to
and inhibiting phosphodiesterase (Roberge
et al. 2004; Sanderson et al. 2000, 2001),
resulting in elevated cAMP. Elevated cAMP
results in increased transcription of CYP19,
increased aromatase activity, and ultimately
increased estrogen production. Although the
effects of atrazine on aromatase vary between
cell lines and tissues, the current study
explains this variation. There are six tissue-
and cell-specific aromatase promoters in
humans. Atrazine affects aromatase expression
only in cell and tissue types that use the
SF-1–dependent ArPII promoter. Tissue
types and cell lines that do not respond to
atrazine are those types that do not utilize
ArPII or that do not express SF-1.
In addition to elucidating the role of SF-1
in atrazine-induced aromatase expression and
explaining variation in responses between cell
types, we developed an assay for detecting
endocrine disruption via aromatase induc-
tion and for distinguishing chemicals that
alter aromatase activity from those that alter
aromatase expression. We confirmed that
atrazine and simazine induce aromatase,
consistent with the literature (Heneweer et al.
2004; Sanderson et al. 2000, 2001, 2002).
The reduction in aromatase by phthalates
(DCHP and DBP) and octylphenol is consis-
tent with their previously reported reduction
in estrogen synthesis (Davis et al. 1994; Kim
et al. 2003; Lovekamp and Davis 2001).
Vinclozolin (which had no effect in the pre-
sent study) increases aromatase, but at con-
centrations 10 times higher than used here
(Sanderson et al. 2002). The other chemicals
examined have not been previously examined
for effects on aromatase. 
The role of SF-1 we identiﬁed in the pre-
sent study is important. Orphan receptors, such
as SF-1, bind their response elements and regu-
late transcription constitutively, but ligand-
binding may enhance their activity. To date,
only phospholipids (Krylova et al. 2005; Li
et al. 2005) have been identiﬁed as endogenous
ligands for SF-1. Here, we show that atrazine
not only elevates cAMP, which also increases
SF-1 expression (Heneweer et al. 2004;
Lehmann et al. 2005; Roberge et al. 2004;
Sanderson et al. 2000), but also binds SF-1
and increases its interaction with ArPII. 
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Figure 6. Kinetic analysis of atrazine binding to SF-1 protein as analyzed by SPR [changes in mass concentration
are detected as differences in the refractive index and shown in resonance units (RU)]. (A) Sensorgrams
of six concentrations of 16PC (the positive control ligand) added to SF-1. (B) Sensorgrams showing
atrazine, benzophenone, or p-nitrotoluene (100 µM each) binding to immobilized SF-1 (only atrazine caused
a signiﬁcant response). (C) Sensorgrams of six concentrations of atrazine added to the immobilized SF-1
(note the dose-dependent response). (D) Sensorgrams showing interactions between atrazine and SF-1 on
a quartz-crystal microbalance. 16PC caused a clear decrease in frequency, demonstrating binding
between the ligand and SF-1; atrazine also substantially decreased the frequency, but ethanol (EtOH) and
the negative control p-nitrotoluene did not.
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InputThe findings of the present study are
important for understanding the negative
impact that atrazine contamination has on
both environmental and public health. In
addition to its vital roles in the reproductive
system, the atrazine-responsive ArPII is also
critically involved in breast cancer oncogene-
sis. The role of estrogen in breast cancer and
the potential role of atrazine exposure is con-
sistent with increased plasma estrogen levels
in several strains of rats when exposed to
atrazine (Eldridge and Wetzel 1999; Eldridge
et al. 1994a, 1994b; Stevens et al. 1994;
Stoker et al. 2000; Wetzel et al. 1994) and
the increased incidence of estrogen-dependent
mammary cancers in rodents (Eldridge et al.
1994a; Stevens et al. 1994; Wetzel et al.
1994). Further, Ueda et al. (2005) showed
that atrazine-induced tumors in rodents are
estrogen-receptor positive. The findings in
rodents are consistent with increased aro-
matase expression and activity in human cell
lines in the present study and in previous
studies (Heneweer et al. 2004, Sanderson
et al. 2000, 2001) and in human tissues
(Roberge et al. 2004). The estrogen that
stimulates breast cancer growth in humans is
derived from both ovarian and extraovarian
sources. Local estrogen production, which
contributes to hormonal stimulation of breast
cancers in breast adipose tissue and fibro-
blasts, is also dependent on ArPII (Bulun
et al. 2005). This extraovarian estrogen plays
a profound mitogenic role in breast tumors
(Bulun et al. 2005): Local estrogen levels in
breast tumors can be 10 times higher than
that in the circulation of postmenopausal
women (Van Landeghem et al. 1985), likely
due to a critical shift in promoter usage from
I.4 (used in normal adipose tissue) to ArPII
(abnormally activated in breast adipose tissue
containing a tumor) (Agarwal et al. 1996;
Harada et al. 1993). Although normal breast
tissue does not typically utilize ArPII, once
transformed, breast cancer cells (malignant
epithelial cells) induce use of ArPII in adja-
cent ﬁbroblasts (Agarwal et al. 1996; Harada
et al. 1993; Utsumi et al. 1996; Zhou et al.
1996). In this regard, the ability of atrazine to
stimulate ArPII is extremely significant.
Atrazine increases the incidence of mammary
cancer in rodents (Eldridge et al. 1994a;
Stevens et al. 1994; Wetzel et al. 1994), and
at least one cohort study in humans showed
that atrazine is associated with breast cancer
in women whose well water is contaminated
with atrazine (Kettles et al. 1997). 
Atrazine induces prostatitis (Stoker et al.
1999) and prostate cancer in rats (Pintér et al.
1980) and was also associated with an 8.4-fold
increase in prostate cancer in men working in
an atrazine production facility in San Gabriel,
Louisiana (Maclennan et al. 2002; Sass 2003).
Although typically considered androgen
dependent, prostate cancer is also estrogen
dependent and is associated with increased
local estrogen production (Christensen and
Lephart 2004; Ellem et al. 2004; Härkönena
and Mäkelä 2004). Aromatase expression and
activity are low in normal prostate cells, but in
malignant cells in the prostate, they increase to
levels comparable with those observed in
breast cancer (Prins and Birch 1997). This
aromatase activity is associated exclusively
with the atrazine-regulated ArPII and renders
the popular antiandrogen treatments for
prostate cancer useless (Ellem et al. 2004).
Also, low levels of estrogen, when bound to
estrogen receptor-α (ER-α), result in prolifer-
ation of the prostate (Ellem et al. 2004). Thus,
in prostate cancer, induction of aromatase via
ArPII in prostate epithelia results in estrogen
synthesis that, in turn, affects the prostate
epithelia in an autocrine/intracrine fashion via
binding to ER-α. Further, elevated estrogens
during early development inhibit prostate
growth but predispose individuals to prostate
disease later in life (Prins and Birch 1997;
Pylkkanen et al. 1993).
In addition to atrazine’s contribution to
adverse health outcomes in humans, the effect
of atrazine on cells and tissues that utilize
ArPII is also signiﬁcant, because all vertebrates
utilize ArPII during gonadal differentiation
and development (Simpson et al. 1994, 2002).
In fact, the activity of atrazine and simazine at
10–7 M (21.57 mol/L) in the present study is
in the range that chemically castrates and
feminizes male amphibians (0.1–20 ppb;
1 ppb = 1 mol/L) (Carr et al. 2003; Hayes
2004, 2005; Hayes et al. 2002a, 2002b, 2003,
2006a, 2006b; McKoy et al. 2002; Miyahara
et al., unpublished data; Reeder et al. 1998;
Tavera-Mendoza et al. 2002) and ﬁsh (6 ppb)
(Moore and Waring 1998). Thus, the present
study is also signiﬁcant because the effects in
wildlife likely occur through the same molecu-
lar mechanisms as documented here; however,
the cell lines and molecular tools are not avail-
able for wildlife species to examine these
effects on this same level.
Considering the prevalence of atrazine in
the environment, the continued rise of cancer
as the leading cause of death in the United
States (breast cancer and prostate cancer are
the most common cancers in men and
women, respectively), the present findings
raise concern for the impact of atrazine on
environmental and public health. This is espe-
cially troubling because African Americans
and Hispanic Americans, more likely to be
occupationally exposed to pesticides and less
likely to have proper access to health care, are
two to four times more likely to die from
breast and prostate cancer, respectively.
The fact that aromatase inhibitors have
proven effective at treating breast cancer
induced by adipose aromatase (Brodie et al.
1999) and promise to have similar therapeutic
value in endometriosis (Shippen and West
2004) underscores the potential role that
atrazine (an aromatase inducer) plays in
increasing the risk of these diseases: Aromatase
expression and estrogen production is exclu-
sively regulated by ArPII and is SF-1 depen-
dent in endometriosis, a disease that affects
4–6 million women (10% of American
women) per year (Bulun et al. 2005). Further,
overexpression of aromatase plays a role in
other diseases including uterine ﬁbroids (uter-
ine leiomyomata), aromatase overexpression
syndrome (Bulun et al. 2005), and polycystic
ovarian syndrome (Pierro et al. 1997). The
many mammalian tissues and cell types that
express SF-1 (and use ArPII) are shown in
Table 1. Given the ubiquity of atrazine con-
tamination, atrazine’s persistence in the envi-
ronment, and the concern for effects of
Atrazine, breast cancer, and prostate cancer
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Table 1. Summary of mammalian tissues and cells that show cAMP/SF-1 dependent, ArPII-like expression
of aromatase.
Tissue/cell type  References
Rat ovary (granulosa)  Carlone and Richards 1997; Falender et al. 2003; 
Fitzpatrick and Richards 1994; Lynch et al. 1993
Rat R2C (Leydig cell carcinoma)  Carlone and Richards 1997; Falender et al. 2003;
Fitzpatrick and Richards 1994 
Rat H540 (Leydig tumor cells)  Young and McPhaul 1997
Human prostate stroma  Ellem et al. 2004
Human prostate tumor (epithelial cells)  Ellem et al. 2004
Human LNCaP (prostate cancer cells)  Ellem et al. 2004
Human Sertoli cells  Gurates et al. 2002
Human endometrial stroma  Gurates et al. 2003
Human corpus luteum  Michael et al. 1995
Human preovulatory follicles  Simpson et al. 1994
Human ovary (granulosa)  Bulun et al. 2005; Sanderson et al. 2000
Human adipose tissue ﬁbroblast  Bulun et al. 2005
Human breast tumor ﬁbroblast  Bulun et al. 2005
Human malignant epithelial cells  Bulun et al. 2005
Human breast cancer adipose tissue  Bulun et al. 2005
Human extra-ovarian endometrium  Bulun et al. 2005
Human ovary-derived endometrial cells  Gurates et al. 2003
Human H295R (adrenal corticocarcinoma)  Sanderson et al. 2000endocrine-disrupting chemicals in wildlife,
especially in amphibian declines (Hayes et al.
2002a, 2002b, 2003, 2006a, 2006b), and in
cancer (Kettles et al. 1997; Maclennan et al.
2002; Sass 2003), the ﬁndings reported here
are quite signiﬁcant. This concern was voiced
several years ago (Sanderson et al. 2000): 
A logical concern would be that exposure to triazine
herbicides, which are produced and used in large
quantities, and are ubiquitous environmental conta-
minants, may similarly contribute to estrogen-
mediated toxicities and inappropriate sexual
differentiation. 
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